目的 系统评价前列环素类似物(prostacyclin analogues,PA)治疗肺动脉高压(pulmonary arterial hypertension ,PAH)的安全性与耐受性。方法 在线检索中国知网、万方、维普、PubMed、Embase等数据库,查找PA治疗PAH的随机对照试验(randomized controlled trial ,RCT),进行文献筛选、数据提取及偏倚评估后,使用RevMan5.3和Stata V 12.0软件进行Meta分析。结果 共纳入16个RCT,3726例患者。Meta分析结果示:试验组至少出现一次不良反应(AE)[RR=1.05,95%CI(1.00,1.10),P=0.04]和停药不良反应的发生率[RR=1.81,95%CI(1.08,3.05),P=0.02]均较对照组高,差异有统计学意义,各具体AE发生趋势前者也较后者高;而至少出现一次严重不良反应的发生率[RR=0.93,95%CI(0.83,1.04),P=0.20],差异无统计学意义。结论 应用PA治疗PAH患者安全性尚可,但仍存在一定的耐受性风险。
Abstract
Objective To evaluate the safety and tolerability of prostacyclin analogues (PA) in the treatment of pulmonary arterial hypertension (PAH).Methods Such databases as CNKI, WanFang Data, VIP, PubMed and Embase were searched for randomized controlled trials (RCTs)in which PAs were used in the treatment of PAH. Literature was screened, data was extracted and the quality of the study was assessed. RevMan5.3 and StataV12.0 software were used for meta-analysis.Results Sixteen RCT studies involving 3,726 patients were included in this research. The result of meta-analysis showed that the incidence of at least one adverse events (AEs)[RR=1.05, 95%CI(1.00, 1.10), P=0.04] and discontinuation [RR=1.81, 95%CI(1.08, 3.05), P=0.02] in the test group was higher than that in the control group, and the difference was statistically significant. The chance of specific AEs in the test group was also higher than in the control group. The incidence rates of at least one serious adverse event [RR=0.93, 95%CI(0.83, 1.04), P=0.20] was not significantly different between the two groups.Conclusions PAs are relatively safe, but there is still the risk of tolerability in PAH patients.
关键词
肺动脉高压 /
前列环素类似物 /
系统评价 /
Meta分析 /
随机对照试验
Key words
pulmonary arterial hypertension /
prostacyclin analogues /
systematic review /
meta-analysis /
randomized controlled trial
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Mclaughlin V, Shah J, Souza R, et al. Management of pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2015, 65(18):1976-1997.
[2] Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension[J]. J Hypertens, 2007, 25(9):1751-1762.
[3] Simonneau G, Torbicki A, Hoeper M, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension[J]. J Med Chem, 2012, 58(18):7128-37.
[4] 刘永贵,赵丽嘉,肖桂芝. Selexipag[J].现代药物与临床,2010,25(6):469-471.
[5] Said, S. I. Mediators and modulators of pulmonary arterial hypertension[J]. Am J Physiol-lung C, 2006, 291(4):L547-L558.
[6] Higgins T, Greene S. Cochrane handbook for systematic reviews of interventions. www.handbook.cochrane.org. Accessed November 5, 2015.
[7] Barst J, Rubin J, Long A, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension[J]. New Engl J Med, 1996, 334(5):296-302.
[8] Badesh B, Tapson F, McGoon D, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial[J]. Ann Inter Med, 2000, 132(6):425-434.
[9] Galie N, Humbert M, Vachiery L, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial[J]. J Am Coll Cardiol, 2002, 39(9):1496-1502.
[10] Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension[J]. New Engl J Med, 2002, 347(5):322-329.
[11] Simonneau G, Barst J, Galie N, et al. Continuous subcutaneous infusion of treprostinil a prostacyclin analogue in patients with pulmonary arterial hypertension[J]. Am J Resp Crit Care, 2002, 165(6):800-804.
[12] Barst J, Mcgoon M, Mclaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2003, 41(12):2119-2125.
[13] Hoeper M, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension[J]. Eur Respir J, 2006, 28(4):691-694.
[14] Mclaughlin V, Oudiz J, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension[J]. Am J Resp Crit Care, 2006, 174(11):1257-1263.
[15] Rubenfire M, Mclaughlin V, Allen P, et al. Transition from Ⅳ epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension[J]. Chest, 2007, 132(3):757-763.
[16] Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial[J]. J Heart Lung Transpl, 2010, 29(2):137-149.
[17] Mclaughlin V, Benza L, Rubin J, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial[J]. J Am Coll Cardiol, 2010, 55(18):1915-1922.
[18] Simonneau G, Torbicki A, Hoeper M, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension[J]. Eur Respir J, 2012, 40(4):874-880.
[19] Tapson F, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study)[J]. Chest, 2012, 142(6):1383-1390.
[20] Jing C, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial[J]. Circulation, 2013, 127(5):624-633.
[21] Tapson F, Jing C, Xu F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study)[J]. Chest, 2013, 144(3):952-958.
[22] Sitbon O, Channick R, Chin M, et al. Selexipag for the treatment of pulmonary arterial hypertension[J]. New Engl J Med, 2015, 373(26):2522-2533.
[23] Edda S, Steven M, Vinicio A, et al. New and emerging therapies for pulmonary arterial hypertension[J]. Annu Rev Med, 2019, 70:45-59.
[24] Galiè N, Humbert M, Vachiery L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2015, 46:903-975.
[25] O’Connell C, Amar D, Athénaïs B, et al. Comparative safety and tolerability of prostacyclins in pulmonary hypertension[J]. Drug Safety, 2016, 39(4):287-294.
[26] Babic T, Browning N. The role of vagal neurocircuits in the regulation of nausea and vomiting[J]. Eur J Pharmacol, 2014, 722:38-47.
[27] Corboz R, Li Z, Malinin V, et al. Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug[J]. J Pharmacol Exp Ther, 2017, 363(3):348-357.
[28] Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension[J]. J Heart Lung Transpl, 2012, 31(7):735-743.
基金
天津市自然科学基金重点项目(15JCZDJC35000);天津市自然科学基金面上项目(18JCYBJC26600)
PDF(1004 KB)
